PARIS (Thomson Financial) - French pharmaceuticals group Ipsen said the US
Food and Drug Administration has given marketing approval for Somatuline Depot
(lanreotide) injections of 60, 90 and 120 mg in the treatment of acromegaly.
The approval is for the treatment's use in patients who have had an
inadequate response to surgery and/or radiotherapy, or for whom surgery and/or
radiotherapy is not an option, the company said.
Somatuline Depot becomes the first product originating from Ipsen's research
and development department to be approved by the FDA and marketed globally, it
said.
The FDA approval triggers a 30 mln eur milestone payment to Ipsen from
Tercica Inc, which has the US and Canada marketing rights for Somatuline Depot.
Tercica expects to launch the drug in the US in the fourth quarter, Ipsen
said.
Andrew.Newby@Thomson.com
an/slj
COPYRIGHT
Copyright AFX News Limited 2007. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by
framing or similar means, is expressly prohibited without the prior written
consent of AFX News.
|